KEYNOTE-689: neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck cancer
Giving pembrolizumab before surgery and continuing it afterwards alongside radiotherapy reduced recurrences in resectable locally advanced head and neck cancer, the first improvement in surgical treatment of the disease in two decades.
Overview
Phase 3 trial of 714 patients with resectable stage III to IVA head and neck squamous cell carcinoma (excluding HPV-positive oropharynx in most analyses) randomised to two cycles of neoadjuvant pembrolizumab followed by surgery and adjuvant pembrolizumab with radiotherapy or chemoradiotherapy, or surgery and adjuvant radiotherapy or chemoradiotherapy alone.
Event-free survival was improved in patients with a PD-L1 combined positive score of 10 or more (median 59.7 versus 26.9 months; hazard ratio 0.66) and of 1 or more (hazard ratio 0.70), and major pathological responses occurred in 9.3 percent after neoadjuvant treatment.
- Combined positive score 10 or more: median event-free survival 59.7 vs 26.9 months; hazard ratio 0.66.
- Combined positive score 1 or more: hazard ratio 0.70.
Perioperative pembrolizumab is a new standard for resectable head and neck cancer with PD-L1 expression, adding immunotherapy to a treatment pathway that had not changed since postoperative chemoradiation was defined.
- Overall survival data immature.
- Pembrolizumab was continued for up to 15 cycles after surgery, adding cost and immune toxicity.
Similar pages
not linked directly; found by shared links- PersonRavindra Uppaluri
Shares KEYNOTE-689, Pembrolizumab.
- Key paperHuman papillomavirus and survival of patients with oropharyngeal cancer (RTOG 0129)
Shares HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer), New England Journal of Medicine.
- Key paperRTOG 9501: postoperative concurrent radiotherapy and chemotherapy for high-risk head and neck squamous cell carcinoma
Shares HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer), New England Journal of Medicine.
- TrialKEYNOTE-412
Shares HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer), Pembrolizumab.
- Key paperKEYNOTE-054 (EORTC 1325): adjuvant pembrolizumab versus placebo in resected stage III melanoma
- PairingImmunotherapy before surgery rather than with chemoradiation (HNSCC)
Shares KEYNOTE-689, Pembrolizumab.
- Key paperRadiotherapy plus cetuximab for locoregionally advanced squamous cell carcinoma of the head and neck
Shares HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer), New England Journal of Medicine.
- Key paperKEYNOTE-826: pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer